A Phase 3b Study to Investigate the Efficacy and Safety of Different Retatrutide Dose Escalation Schemes in Participants Without Type 2 Diabetes Who Have Obesity or Overweight: A Randomized, Controlled, Double-Blind Trial

ReclutandoFase 3ClinicalTrials.gov

ID: NCT07357415Tipo: INTERVENTIONALInicio: 24 de ene de 2026Fin estimado: 1 de nov de 2028

Traducción no disponible, mostrando original

Resumen

The purpose of this study is to investigate the efficacy and safety of different retatrutide dose escalation schemes in participants without type 2 diabetes who have obesity or overweight. Participation in the study will last about 113 weeks.

Elegibilidad

Edad mínima: 18 YearsSexo: ALL

Criterios de inclusión

Have a Body Mass Index (BMI) at screening
≥ 30 kilogram per square meter (kg/m2) OR
≥ 27 kg/m2 with presence of at least one of the following weight-related conditions at screening: high blood pressure, abnormal levels of lipid, obstructive sleep apnea, heart disease
Have at least one unsuccessful attempt to lose weight by dieting

Criterios de exclusión

Have a self-reported change in body weight \>5 kilograms (kg) (11 pounds) within 90 days before screening
Have a prior or planned surgical treatment for obesity
Have type 1 diabetes or type 2 diabetes
Have a family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2)
Have had within the past 90 days before screening:
heart attack
stroke
hospitalization for unstable angina or heart failure
Have New York Heart Association Functional Classification Class IV congestive heart failure
Have a history of chronic or acute pancreatitis
Have taken weight loss drugs, including over-the counter medications within 90 days prior to screening

Intervenciones

drug

Retatrutide

Administered SC

Ubicaciones

Cicemo Srl

Buenos Aires, Argentina

NOT_YET_RECRUITING

CARDIAMET Investigaciones Médicas

Buenos Aires, Argentina

NOT_YET_RECRUITING

Stat Research S.A.

Buenos Aires, Argentina

NOT_YET_RECRUITING

Centro de Investigaciones Metabólicas (CINME)

Buenos Aires, Argentina

NOT_YET_RECRUITING

Centro Médico Viamonte

Buenos Aires, Argentina

NOT_YET_RECRUITING

Patrocinadores

PrincipalEli Lilly and Company

Contactos

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or

CONTACT

LillyTrials@Lilly.com 1-317-615-4559

Physicians interested in becoming principal investigators please contact

CONTACT

clinical_inquiry_hub@lilly.com

Aviso: La información de este ensayo proviene de fuentes públicas y tiene carácter exclusivamente informativo. No constituye asesoramiento médico, regulatorio ni de ningún otro tipo. Las traducciones son automatizadas y no poseen validez oficial. Consultá siempre con un profesional de la salud. Ver Términos de Uso.

A Phase 3b Study to Investigate the Efficacy and Safety o... | EligiMed